Abstract
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have markedly enhanced survival rates among patients with advanced non-small cell lung cancer (NSCLC) exhibiting EGFR mutations. However, acquired resistance diminishes their therapeutic efficacy over time. Recent investigations have linked intracellular cholesterol with the emergence and advancement of various cancers. Elevated cholesterol levels could correlate with resistance to EGFR-TKIs in NSCLC. This review examines the association between cholesterol and EGFR-TKI resistance in NSCLC, with the objective of identifying more effective treatments and surmounting resistance.